PDF) Eloralintide, a selective, longacting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept Eloralintide Lilly's Amylin Agonist Outperforms Novo's Cagrilintide at 48 Weeks Amylin based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management, type 2 diabetes and more! Eloralintide, a selective amylin receptor agonist Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet